Systematic review and meta-analysis of the evidence for flexible sigmoidoscopy as a screening method for the prevention of colorectal cancer

British Journal of Surgery

Volumn 99, Issue 11, 2012, Pages 1488-1500

  Littlejohn, C ^a   Hilton, S ^a   MacFarlane, G J ^b   Phull, P ^c  

^a NHS GRAMPIAN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867103707     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.8882     Document Type: Article

References (47)

1. Cancer Research UK. Bowel Cancer Statistics. http://info. cancerresearchuk.org/cancerstats/types/bowel/?a=5441 [accessed 15 March 2011].
2. Centers for Disease Control and Prevention. Colorectal Cancer Statistics. http://www.cdc.gov/cancer/colorectal/statistics [accessed 7 December 2011].
3. Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, et al., Colon cancer. Crit Rev Oncol Hematol 2010; 74: 106-133.
4. Saif MW, Chu E,. Biology of colorectal cancer. Cancer J 2010; 16: 196-201.
5. Hardcastle JD, Chamberlain JO, Robinson MHE, Moss SM, Amar SS, Blafour TW, et al., Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-1477.
6. Kronborg O, Fenger C, Olsen J, JÃrgensen, SÃndergaard O,. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-1471.
7. US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 627-637.
8. National Screening Committee. First Report of the National Screening Committee. http://www.dh.gov.uk/en/Publication sandstatistics/Publications/ PublicationsPolicyAndGuidance/ DH-4006774 [accessed 3 May 2012].
9. Atkin WS, Cuzick J, Northover JMA, Whynes DK,. Prevention of colorectal cancer by once-only sigmoidoscopy. Lancet 1993; 341: 736-740.
10. Scottish Intercollegiate Guidelines Network (SIGN). SIGN 50: A Guideline Developer's Handbook. SIGN: Edinburgh, 2008. http://www.sign.ac.uk/guidelines/ fulltext/50/index.html [accessed 13 December 2010].
11. Ioannidis JPA, Patsopoulos NA, Rothstein HR,. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ 2008; 336: 1413-1415.
12. Walsh JME, Terdiman JP,. Colorectal cancer screening: scientific review. JAMA 2003; 289: 1288-1296.
13. Hakama M, Hoff G, Kronborg O, PÃ¥hlman L,. Screening for colorectal cancer. Acta Oncol 2005; 44: 425-439.
14. Nicholson FB, Barro JL, Atkin W, Lilford R, Patnick J, Williams CB, et al., Review article: population screening for colorectal cancer. Aliment Pharmacol Ther 2005; 22: 1069-1077.
15. Hayee BH, Chung-Faye G,. Colorectal cancer screening. Clin Med 2006; 6: 453-456.
16. Kerr J, Day P, Broadstock M, Weir R, Bidwell S,. Systematic review of the effectiveness of population screening for colorectal cancer. N Z Med J 2007; 120: U2629.
17. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al., Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134: 1570-1595.
18. Hviding K, Juvet LK, Vines D, Fretheim A,. Colorectal Cancer Screening-Effect on Mortality and Incidence Rate of Colorectal Cancer. Overview of Documentation and International Recommendations. Norwegian Knowledge Centre for the Health Services, 2008. http://hera.openrepository.com/hera/bitstream/ 10143/64536/1/NOKCrapport30-2008.pdf [accessed 21 December 2010].
19. Canadian Task Force Preventive Health Care. Colorectal cancer screening. Recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ 2001; 165: 206-208.
20. Atkin WS, Hart A, Edwards R, McIntyre P, Aubrey R, Wardle J, et al., Uptake, yield of neoplasia, and adverse effects of flexible sigmoidoscopy screening. Gut 1998; 42: 560-565.
21. Atkin WS, Cook CF, Cuzick J, Edwards R, Northover JM, Wardle J,; UK Flexible Sigmoidoscopy Screening Trial Investigators (UKFSSTI). Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002; 359: 1291-1300.
22. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JMA, et al., Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multi-centre randomised controlled trial. Lancet 2010; 375: 1624-1633.
23. Segnan N, Senore C, Andreoni B, Aste H, Bonelli L, Crosta C, et al., Baseline findings of the Italian multicenter randomized controlled trial of 'once-only sigmoidoscopy'-SCORE. J Natl Cancer Inst 2002; 94: 1763-1772.
24. Bonelli L, Sciallero S, Senore C, Zappa M, Aste H, Andreoni B, et al.,; SCORE Working Group. History of negative colorectal endoscopy and risk of rectosigmoid neoplasms at screening flexible sigmoidoscopy. Int J Colorectal Dis 2006; 21: 105-113.
25. Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, et al.,; SCORE Working Group. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the italian randomized controlled trial-SCORE. J Natl Cancer Inst 2011; 103: 1310-1322.
26. Weissfeld JL, Schoen RE, Pinsky PF, Bresalier RS, Church T, Yurgalevitch S, et al., Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst 2005; 97: 989-997.
27. Schoen RE, Pinsky PF, Weissfeld JL, Bresalier RS, Church T, Prorok P, et al.,; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Group. Results of repeat sigmoidoscopy 3 years after a negative examination. JAMA 2003; 290: 41-48.
28. Berry DP, Clarke P, Hardcastle JD, Vellacott KD,. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening. Br J Surg 1997; 84: 1274-1276.
29. Brevinge H, Lindholm E, Buntzen S, Kewenter J,. Screening for colorectal neoplasia with faecal occult blood testing compared with flexible sigmoidoscopy directly in a 55-56 years' old population. Int J Colorectal Dis 1997; 12: 291-295.
30. Verne JECW, Aubrey R, Love SB, Talbot IC, Northover JM,. Population based randomised study of uptake and yield of screening by flexible sigmoidoscopy compared with screening by faecal occult blood testing. BMJ 1998; 317: 182-185.
31. Rasmussen M, Kronborg O, Fenger C, JÃrgensen OD,. Possible advantages and drawbacks of adding flexible sigmoidoscopy to hemoccult-II in screening for colorectal cancer. A randomized study. Scand J Gastroenterol 1999; 34: 73-78.
32. Thiis-Evensen E, Hoff GS, Sauar J, Langmark F, Majak BM, Vatn MH,. Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol 1999; 34: 414-420.
33. Hoff G, Thiis-Evensen E, Grotmol T, Sauar J, Vatn MH, Moen IE,. Do undesirable effects of screening affect all-cause mortality in flexible sigmoidoscopy programmes? Experience from the Telemark Polyp Study 1983-1996. Eur J Cancer Prev 2001; 10: 131-137.
34. Thiis-Evensen E, Hoff GS, Sauar J, Majak BM, Vatn MH,. The effect of attending a flexible sigmoidoscopic screening program on the prevalence of colorectal adenomas at 13-year follow-up. Am J Gastroenterol 2001; 96: 1901-1907.
35. Gondal T, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G,. The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years. Scand J Gastroenterol 2003; 38: 635-642.
36. Hoff G, Grotmol T, Skovlund E, Bretthauer M,; Norwegian Colorectal Cancer Prevention Study Group. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 2009; 338: b1846.
37. Segnan N, Senore C, Andreoni B, Segnan N, Senore C, Andreoni B, et al.,; SCORE2 Working Group-Italy. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. J Natl Cancer Inst 2005; 97: 347-357.
38. Senore C, Armaroli P, Silvani M, Andreoni B, Bisanti L, Marai L, et al., Comparing different strategies for colorectal cancer screening in Italy: predictors of patients' participation. Am J Gastroenterol 2010; 105: 188-198.
39. Multicentre Australian Colorectal-neoplasia Screening (MACS) Group. The comparison of colorectal neoplasia screening tests: a multicentre community-based study of the impact of consumer choice. Med J Aust 2006; 184: 546-550.
40. Segnan N, Senore C, Andreoni B, Azzoni A, Bisanti L, Cardelli A, et al.,; SCORE3 Working Group-Italy. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and fit for colorectal cancer screening. Gastroenterology 2007; 132: 2304-2312.
41. Fracchia M, Senore C, Armaroli P, Ferraris R, Placido RD, Musso A, et al., Assessment of the multiple components of the variability in the adenoma detection rate in sigmoidoscopy screening, and lessons for training. Endoscopy 2010; 42: 448-455.
42. Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JC, et al., Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010; 59: 62-68.
43. Hol L, de Jonge V, van Leerdam ME, van Ballegooijen M, Looman CW, van Vuuren AJ, et al., Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Eur J Cancer 2010; 46: 2059-2066.
44. Lansdorp-Vogelaar I, Knudsen AB, Brenner H,. Cost-effectiveness of colorectal cancer screening-an overview. Best Pract Res Clin Gastroenterol 2010; 24: 439-449.
45. Whyte S, Chilcott J, Cooper K, Essat M, Stevens J, Wong R,. Re-appraisal of the Options for Colorectal Cancer Screening FULL REPORT: Report for the NHS Bowel Cancer Screening Programme School of Health and Related Research (ScHARR). University of Sheffield: Sheffield, 2011.
46. Liberati A, Altman DG, Tetzlaff J, Mulrow C, GÃtzsche PC, Ioannidis JP, et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6: e1000100.
47. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. PLoS Med 2009; 6: e1000097.